KLP Kapitalforvaltning AS Has $387,000 Stock Holdings in Mirum Pharmaceuticals, Inc. $MIRM

KLP Kapitalforvaltning AS grew its position in shares of Mirum Pharmaceuticals, Inc. (NASDAQ:MIRM) by 13.4% in the second quarter, HoldingsChannel reports. The fund owned 7,600 shares of the company’s stock after acquiring an additional 900 shares during the period. KLP Kapitalforvaltning AS’s holdings in Mirum Pharmaceuticals were worth $387,000 as of its most recent SEC filing.

Other large investors have also recently bought and sold shares of the company. CWM LLC boosted its position in Mirum Pharmaceuticals by 259.4% during the 1st quarter. CWM LLC now owns 593 shares of the company’s stock worth $27,000 after acquiring an additional 428 shares during the last quarter. Comerica Bank boosted its position in Mirum Pharmaceuticals by 45.1% during the 1st quarter. Comerica Bank now owns 895 shares of the company’s stock worth $40,000 after acquiring an additional 278 shares during the last quarter. Quarry LP acquired a new position in Mirum Pharmaceuticals during the 1st quarter worth approximately $56,000. Mirae Asset Global Investments Co. Ltd. boosted its position in Mirum Pharmaceuticals by 14.9% during the 2nd quarter. Mirae Asset Global Investments Co. Ltd. now owns 1,914 shares of the company’s stock worth $97,000 after acquiring an additional 248 shares during the last quarter. Finally, KBC Group NV acquired a new position in Mirum Pharmaceuticals during the 1st quarter worth approximately $89,000.

Wall Street Analyst Weigh In

MIRM has been the subject of a number of recent research reports. JPMorgan Chase & Co. upped their price target on Mirum Pharmaceuticals from $53.00 to $77.00 and gave the stock an “overweight” rating in a research report on Friday, September 12th. HC Wainwright upped their price target on Mirum Pharmaceuticals from $73.00 to $80.00 and gave the stock a “buy” rating in a research report on Thursday, August 7th. Evercore ISI increased their price objective on Mirum Pharmaceuticals from $77.00 to $89.00 and gave the company an “outperform” rating in a report on Friday, August 8th. TD Cowen raised Mirum Pharmaceuticals to a “strong-buy” rating in a report on Thursday, September 25th. Finally, Morgan Stanley increased their price objective on Mirum Pharmaceuticals from $75.00 to $81.00 and gave the company an “overweight” rating in a report on Thursday. Two research analysts have rated the stock with a Strong Buy rating, nine have assigned a Buy rating and one has issued a Sell rating to the company. According to data from MarketBeat, the stock currently has an average rating of “Buy” and a consensus target price of $79.70.

Mirum Pharmaceuticals Stock Down 1.2%

Shares of NASDAQ MIRM opened at $73.53 on Monday. The company has a debt-to-equity ratio of 1.21, a quick ratio of 2.97 and a current ratio of 3.13. Mirum Pharmaceuticals, Inc. has a 52 week low of $36.88 and a 52 week high of $78.54. The stock has a market capitalization of $3.69 billion, a P/E ratio of -60.77 and a beta of 0.81. The stock’s fifty day moving average is $72.58 and its 200 day moving average is $55.86.

Mirum Pharmaceuticals (NASDAQ:MIRM) last issued its quarterly earnings results on Wednesday, August 6th. The company reported ($0.12) EPS for the quarter, topping analysts’ consensus estimates of ($0.31) by $0.19. Mirum Pharmaceuticals had a negative return on equity of 24.76% and a negative net margin of 13.65%.The company had revenue of $127.79 million for the quarter, compared to analysts’ expectations of $107.91 million. During the same quarter last year, the business earned ($0.52) earnings per share. Mirum Pharmaceuticals’s revenue was up 64.1% on a year-over-year basis. Sell-side analysts forecast that Mirum Pharmaceuticals, Inc. will post -1.43 earnings per share for the current fiscal year.

Insider Buying and Selling

In related news, Director Laura Brege sold 17,000 shares of the firm’s stock in a transaction on Thursday, September 11th. The stock was sold at an average price of $74.40, for a total value of $1,264,800.00. Following the transaction, the director owned 15,703 shares in the company, valued at approximately $1,168,303.20. This trade represents a 51.98% decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. Also, CFO Eric Bjerkholt sold 9,578 shares of the firm’s stock in a transaction on Friday, September 12th. The stock was sold at an average price of $76.01, for a total value of $728,023.78. Following the completion of the transaction, the chief financial officer owned 39,945 shares in the company, valued at $3,036,219.45. The trade was a 19.34% decrease in their position. The disclosure for this sale can be found here. Insiders have sold a total of 116,578 shares of company stock worth $7,262,824 over the last three months. Company insiders own 22.87% of the company’s stock.

Mirum Pharmaceuticals Company Profile

Mirum Pharmaceuticals, Inc, a biopharmaceutical company, focuses on the development and commercialization of novel therapies for debilitating rare and orphan diseases. Its lead product candidate is LIVMARLI (maralixibat), an orally administered and minimally absorbed ileal bile acid transporter (IBAT) inhibitor that is approved for the treatment of cholestatic pruritus in patients with Alagille syndrome in the United States and internationally.